VNDA Vanda Pharmaceuticals Inc.

14.45
+0  (3%)
Previous Close 14.05
Open 14.10
Price To book 4.71
Market Cap 640.80M
Shares 44,346,000
Volume 497,841
Short Ratio 3.61
Av. Daily Volume 579,923

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 enrolment to commence 4Q 2016 with data due 2H 2017
Tradipitant
Gastroparesis
PK trial to be initiated 2018.
HETLIOZ (tasimelteon) - pediatric formulation
Insomnia
Approved May 26, 2016.
Fanapt
Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.
Approved January 31, 2014.
HETLIOZ (tasimelteon)
Insomnia
Phase 2 data due in 2H 2017.
HETLIOZ (tasimelteon)
Jet Lag Disorder
Phase 3 initiated 4Q 2016. Data due 2018.
HETLIOZ (tasimelteon)
Smith-Magenis Syndrome
Phase 2 data due in mid-2017.
VLY-686 (tradipitant)
Chronic pruritus in patients with atopic dermatitis

Latest News

  1. Vanda Pharmaceuticals, Inc. – Value Analysis (NASDAQ:VNDA) : April 20, 2017
  2. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : April 19, 2017
  3. Vanda Pharmaceuticals to Announce First Quarter 2017 Financial Results on May 2, 2017
  4. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : March 31, 2017
  5. Vanda and UCSF Announce License Agreement for CFTR Activators and Inhibitors
  6. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : March 7, 2017
  7. Vanda Pharmaceuticals Announces Participation at March 2017 Investor Conferences
  8. Vanda Pharmaceuticals, Inc. :VNDA-US: Earnings Analysis: Q4, 2016 By the Numbers : February 22, 2017
  9. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : VNDA-US : February 21, 2017
  10. Edited Transcript of VNDA earnings conference call or presentation 15-Feb-17 9:30pm GMT
  11. Vanda reports 4Q loss
  12. Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results
  13. Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2016 Financial Results on February 15, 2017
  14. Merck KGaA Expands Distribution Deal with Roche (revised)
  15. D.C.-area biotech stocks fall on Trump's tough talk on industry
  16. Jefferies Has 5 Top Biotech Stocks to Buy for 2017
  17. Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance
  18. Vanda Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : VNDA-US : January 2, 2017
  19. Abbott Labs to Close St. Jude Acquisition Later this Week